Impact of peer tutoring sessions on oral language vocabulary in early childhood inclusive settings

Researchers agree that developing high quality programs using evidence based practice and active participation from students with disabilities, who receive instruction with typical peers, is critical to overall student achievement and success of inclusive practice (Bailey, McWilliam, Buysse, & Wesley, 1998; Villa, Thousand, Meyers, & Nevin, 1996; Volz, Brazil, & Ford, 2001). Identifying what interventions are necessary in order to support the developmental objectives and positive outcomes of young children remains a priority concern (Cavallaro, Ballard-Rosa, & Lynch, 1998). This study addressed the following questions: (a) Do peer tutoring sessions in early childhood settings increase oral language vocabulary in students with disabilities who have language delay? (b) Do peer tutoring sessions generalize use of learned vocabulary to a new classroom setting by students with disabilities who have language delay? (c) Does a balanced model of peer tutoring maintain new vocabulary use between the tutee and typical peers in an independent choice center following the tutoring sessions? An examination of the effects of peer tutoring sessions in order to improve oral vocabulary for young students with disabilities were addressed; The goals of the study were: (a) to investigate peer tutoring sessions and vocabulary growth in young students with disabilities who have language delays, (b) to measure oral vocabulary growth over a six week period, (c) to analyze student use of vocabulary in classroom interest centers, (d) to promote the findings from this study in order to improve educator and family access and understanding of peer tutoring across settings and (e) to demonstrate a balanced model of peer tutoring and the gains for the tutee and the tutor; A pretest was conducted in order to determine current vocabulary levels for the participants in this study. The results of peer tutoring as an intervention were summarized after six weeks of the study. Students with disabilities increased oral language vocabulary when typical peers modeled new words and followed the peer tutoring steps

Program-Wide Positive Behavior Support in Preschool: Lessons for Getting Started

There is growing concern over the number of young children who display challenging behavior and preschool teachers are reporting children’s challenging behavior as their greatest concern. Program-wide Positive Behavior Support (PWPBS) is a promising model for supporting appropriate behavior and decreasing challenging behavior in early childhood programs. Implementation in early childhood settings is relatively new and guidance on how to implement PWPBS in early childhood settings in growing. This article documents the implementation process for an early childhood program serving children from six weeks to five years of age, shares lessons learned and offers practical advice for getting started with PWPBS

Eliminating Exclusionary Practices in Early Childhood Education in Nevada

Problem. Many young children under 5 years old spend a significant part of their days in early childhood settings which provide them access to environments and activities that foster their learning. Unfortunate- ly, in many of these early childhood settings, young children are expelled and suspended at a rate that is three times the rate of students in a K-12 setting leading to detrimental, long-term outcomes for young children, families, and the community. Purpose. This paper gives an overview of exclusionary practices in early childhood, discusses causes and consequences of these practices, and provides recommendations to eliminate exclusionary practices in Nevada. Recommendations. To reduce exclusionary practices, it is recommended to embed preventive practices into early childhood state requirements; develop data sys- tems to better understand and track practices; deliver high quality professional development and technical assistance; use developmental screening and referrals for young children in need; and increasing family engagement

Lipid degradation promotes prostate cancer cell survival

Prostate cancer is the most common male cancer and androgen receptor (AR) is the major driver of the disease. Here we show that Enoyl-CoA delta isomerase 2 (ECI2) is a novel AR-target that promotes prostate cancer cell survival. Increased ECI2 expression predicts mortality in prostate cancer patients (p = 0.0086). ECI2 encodes for an enzyme involved in lipid metabolism, and we use multiple metabolite profiling platforms and RNA-seq to show that inhibition of ECI2 expression leads to decreased glucose utilization, accumulation of fatty acids and down-regulation of cell cycle related genes. In normal cells, decrease in fatty acid degradation is compensated by increased consumption of glucose, and here we demonstrate that prostate cancer cells are not able to respond to decreased fatty acid degradation. Instead, prostate cancer cells activate incomplete autophagy, which is followed by activation of the cell death response. Finally, we identified a clinically approved compound, perhexiline, which inhibits fatty acid degradation, and replicates the major findings for ECI2 knockdown. This work shows that prostate cancer cells require lipid degradation for survival and identifies a small molecule inhibitor with therapeutic potential.</p

multi‐patient dose synthesis of [18F]Flumazenil via a copper‐mediated 18F‐fluorination

Background Flumazenil (FMZ) is a functionally silent imidazobenzodiazepine which binds to the benzodiazepine binding site of approximately 75% of the brain γ-aminobutyric acid-A receptors (GABAARs). Positron Emission Tomography (PET) imaging of the GABAARs with [11C]FMZ has been used to evidence alterations in neuronal density, to assess target engagement of novel pharmacological agents, and to study disorders such as epilepsy and Huntington’s disease. Despite the potential of FMZ PET imaging the short half-life (t1/2) of carbon-11 (20 min) has limited the more widespread clinical use of [11C]FMZ. The fluorine-18 (18F) isotopologue with a longer t1/2 (110 min) is ideally suited to address this drawback. However, the majority of current radiochemical methods for the synthesis of [18F]FMZ are non-trivial and low yielding. We report a robust, automated protocol that is good manufacturing practice (GMP) compatible, and yields multi-patient doses of [18F]FMZ. Results The fully automated synthesis was developed on the Trasis AllinOne (AIO) platform using a single-use cassette. [18F]FMZ was synthesized in a one-step procedure from [18F]fluoride, via a copper-mediated 18F-fluorination of a boronate ester precursor. Purification was performed by semi-preparative radio-HPLC and the collected fraction formulated directly into the final product vial. The overall process from start of synthesis to delivery of product is approximately 55 min. Starting with an initial activity of 23.6 ± 5.8 GBq (n = 3) activity yields of [18F]FMZ were 8.0 ± 1 GBq (n = 3). The synthesis was successfully reproduced at two independent sites, where the product passed quality control release criteria in line with the European Pharmacopoeia standards and ICH Q3D(R1) guidelines to be suitable for human use. Conclusion Reported is a fully automated cassette-based synthesis of [18F]FMZ that is Good Manufacturing Practice (GMP) compatible and produces multi-patient doses of [18F]FMZ

Multi-patient dose synthesis of [18F]Flumazenil via a copper-mediated 18F-fluorination.

peer reviewed("[en] BACKGROUND: Flumazenil (FMZ) is a functionally silent imidazobenzodiazepine which binds to the benzodiazepine binding site of approximately 75% of the brain γ-aminobutyric acid-A receptors (GABAARs). Positron Emission Tomography (PET) imaging of the GABAARs with [11C]FMZ has been used to evidence alterations in neuronal density, to assess target engagement of novel pharmacological agents, and to study disorders such as epilepsy and Huntington's disease. Despite the potential of FMZ PET imaging the short half-life (t1/2) of carbon-11 (20 min) has limited the more widespread clinical use of [11C]FMZ. The fluorine-18 (18F) isotopologue with a longer t1/2 (110 min) is ideally suited to address this drawback. However, the majority of current radiochemical methods for the synthesis of [18F]FMZ are non-trivial and low yielding. We report a robust, automated protocol that is good manufacturing practice (GMP) compatible, and yields multi-patient doses of [18F]FMZ. RESULTS: The fully automated synthesis was developed on the Trasis AllinOne (AIO) platform using a single-use cassette. [18F]FMZ was synthesized in a one-step procedure from [18F]fluoride, via a copper-mediated 18F-fluorination of a boronate ester precursor. Purification was performed by semi-preparative radio-HPLC and the collected fraction formulated directly into the final product vial. The overall process from start of synthesis to delivery of product is approximately 55 min. Starting with an initial activity of 23.6 ± 5.8 GBq (n = 3) activity yields of [18F]FMZ were 8.0 ± 1 GBq (n = 3). The synthesis was successfully reproduced at two independent sites, where the product passed quality control release criteria in line with the European Pharmacopoeia standards and ICH Q3D(R1) guidelines to be suitable for human use. CONCLUSION: Reported is a fully automated cassette-based synthesis of [18F]FMZ that is Good Manufacturing Practice (GMP) compatible and produces multi-patient doses of [18F]FMZ.","[en] ",""

Lipid degradation promotes prostate cancer cell survival

Prostate cancer is the most common male cancer and androgen receptor (AR) is the major driver of the disease. Here we show that Enoyl-CoA delta isomerase 2 (ECI2) is a novel AR-target that promotes prostate cancer cell survival. Increased ECI2 expression predicts mortality in prostate cancer patients (p = 0.0086). ECI2 encodes for an enzyme involved in lipid metabolism, and we use multiple metabolite profiling platforms and RNA-seq to show that inhibition of ECI2 expression leads to decreased glucose utilization, accumulation of fatty acids and down-regulation of cell cycle related genes. In normal cells, decrease in fatty acid degradation is compensated by increased consumption of glucose, and here we demonstrate that prostate cancer cells are not able to respond to decreased fatty acid degradation. Instead, prostate cancer cells activate incomplete autophagy, which is followed by activation of the cell death response. Finally, we identified a clinically approved compound, perhexiline, which inhibits fatty acid degradation, and replicates the major findings for ECI2 knockdown. This work shows that prostate cancer cells require lipid degradation for survival and identifies a small molecule inhibitor with therapeutic potential.status: publishe